Zhejiang Kanying Import & Export Co. Ltd 86--17169758851 kanyingexport@gmail.com
USP31 Essential Antibiotic API

USP31 Essential Antibiotic API

  • High Light

    Essential Antibiotic API Powder

    ,

    USP31 Essential Antibiotic API

    ,

    cas 144701-48-4 powder

  • Molecular Formula
    C33H30N4O2
  • CAS
    144701-48-4
  • Product Name
    Telmisartan
  • Quality Standard
    USP31
  • Appearance
    White Or Quasi-white Crystalline Powder
  • Shelf Life
    2 Years
  • Brand Name
    Kan Ying
  • Boiling Point
    771.9±70.0 °C At 760 MmHg
  • Melting Point
    261-263°C
  • Point Of Flammability
    420.6±35.7 °C
  • Place of Origin
    India
  • Brand Name
    Kan Ying
  • Minimum Order Quantity
    1KG
  • Price
    To discuss
  • Packaging Details
    1KG/25KG
  • Delivery Time
    2
  • Payment Terms
    L/C, D/A, D/P, T/T, Western Union, MoneyGram,Dollars
  • Supply Ability
    2000000

USP31 Essential Antibiotic API

Essential hypertension Reduce cardiovascular disease Antibiotic API buck

 

*  Product title: telmisartan

*  Product Description:

 

Telmisartan tablet is a compound antihypertensive drug, which contains two types of antihypertensive components, one is ARB class; The other is a diuretic. The combination of these two drugs is a relatively advantageous combination. The ARB class drugs can prevent left ventricular remodeling, reduce proteinuria, and improve the survival rate of patients with heart failure.

 

*  Product parameter table:

 

 

density

1.2±0.1 g/cm3

boiling point

771.9±70.0 °C at 760 mmHg

                     melting point

261-263°C

Molecular formula

C33H30N4O2

      The molecular weight

514.617

point of flammability

420.6±35.7 °C

                   Precise quality

514.236877
PSA 72.94000
LogP 7.73
external properties White or off-white crystalline powder
vapour pressure 0.0±2.8 mmHg at 25°C
refractive index 1.667
storage condition Hygroscopic, -20°C Freezer, Under Inert Atmosphere
Water solubility insoluble
molecular structure

1. Molar refractive index: 154.51

2. Molar volume (cm3/mol) : 414.9

3. Equivalent specific volume (90.2K) : 1096.2

4, surface tension (dyne/cm) : 48.7

5. Polarizability (10-24cm3) : 61.25

 

*  Product Advantages:

 

The antihypertensive effect was stable and significant.

Lower incidence of impotence and cough;

It has a good diuretic effect.

Can improve the myocardial stenosis disorder;

Reduces the risk of death from myocardial infarction, stroke, or cardiovascular disease.

 

*  Clinical characteristics:


1. Pharmacokinetics showed that the action was rapid (0.3h) and lasted for a long time (35.4h), and the effect on heart rate was small when hypotension was reduced.

 

2. Comparison with enalapril: the antihypertensive effect is better than enalapril, and the effect is still better than telmisartan when the two are used together with diuretics, and the cough incidence is less.

 

3. Compared with lisinopril: the antihypertensive (systolic and diastolic) effect was more obvious, and the incidence of cough in telmisartan group (16%) was significantly lower than that in lisinopril group (60%).

 

4. Compared with atenolol: the antihypertensive effect is similar, and the incidence of side effects (impotence and fatigue) is low.

 

5. Compared to amlodipine, the telmisartan group significantly reduced heart rate within four hours of taking the drug and between 6:00 a.m. and 12:00 a.m.

 

In conclusion, telmisartan has the following characteristics compared with other antihypertensive drugs:

It has specificity of receptor action.

Antihypertensive effect is remarkable.

It has a good diuretic effect.

Can improve myocardial stenosis disorder.

 

* Matters needing attention:

 

1. Symptomatic hypotension should be treated with supportive therapy when overdose of this product occurs. This product cannot be cleared by hemodialysis.

 

2. This product may increase the hypotensive effect of antihypertensive drugs.

 

3. Serum lithium levels should be monitored when taken in combination with certain drugs

 

4. There is no need to adjust the dosage of this product in patients with mild to moderate renal impairment, and the dosage should not exceed 40 mg daily in patients with mild to moderate hepatic impairment.

 

5. Pregnant women and lactating women are prohibited from using this product.

 

6. The safety of using this product in children has not been established, and children should be used with caution.

 

*  Pictures of the product:

 

USP31 Essential Antibiotic API 0USP31 Essential Antibiotic API 1